Robert Daniels

Robert Daniels is a Venture Partner at Brandon Capital Partners, based in Sydney, New South Wales, Australia. Prior to joining the investment firm in 2021, he served as Director and Chief Executive Officer of Elastagen Pty Ltd from 2008 to 2018. During his decade-long tenure, he guided the biotechnology startup from its initial university laboratory spin-out phase through extensive clinical pipeline development. This leadership culminated in the company's successful acquisition by Allergan for approximately A$350 million and its subsequent operational integration into AbbVie. His academic credentials include a Bachelor of Science from the University of Leeds, a doctorate from University College London, and a Master of Entrepreneurship and Innovation from Swinburne University's Australian Graduate School of Entrepreneurship. Daniels currently focuses on advising early-stage life science investments and commercializing science-based therapeutics and healthcare devices for global pharmaceutical markets.